Chao-Lin Kuo

Chao-Lin Kuo

Auto-generated profile, based on publicly available information

Chao-Lin Kuo

Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources China Medical University Taichung Taiwan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2022 in In Vivo
Verified
Journal Article
Open access
PDF file
JKJung-Yu Kuo
Jung-Yu Kuo
CLChing-Lung Liao
Ching-Lung Liao
YMYi-Shih Ma
Yi-Shih Ma
CKChao-Lin Kuo
Chao-Lin Kuo
JCJaw-Chyun Chen
Jaw-Chyun Chen
JCJing-Gung Chung
Jing-Gung Chung
Background/Aim: Lung cancer notably contributes to tumor-associated mortality worldwide, and standard chemotherapy is used for lung cancer patients. However, its therapeutic efficacy remains unsatisfactory. This study aimed to evaluate the effects and molecular mechanisms of sorafenib and bufalin combination therapy on lung cancer cells in vitro. Materials and Methods: NCI-H292 cells were treated with sorafenib, bufalin, and sorafenib in combination with bufalin. Cell viability, ROS production, Ca2+ release, and mitochondrial membrane potential were examined by flow cytometric assay. Annexin V/PI staining and chromatin condensation were examined by the apoptosis assays. Finally the molecular mechanism of apoptosis-associated protein expression was investigated by western blotting. Results: NCI-H292 cells treated with sorafenib in combination with bufalin showed significantly decreased viability, enhanced cellular apoptosis, and DNA condensation when compared to that with sorafenib or bufalin alone. Moreover, the combination treatment exhibited higher reactive oxygen species (ROS) production and lower mitochondrial membrane potential (ΔΨm). The combined treatment resulted in higher expression of SOD but lower catalase compared to sorafenib treatment alone. Compared to sorafenib or bufalin treatment alone, the combination treatment resulted in lower Bcl-2 expression but higher Bax, Bad, APAF-1, caspase-3, and caspase-9. Conclusion: Sorafenib in combination with bufalin shows more potent cytotoxic effects and cell apoptosis than sorafenib or bufalin treatment alone in NCI-H292 cells. The combined treatment significantly enhanced apoptotic cell death in NCI-H292 lung cancer cells by activating ROS-, mitochondria-, and caspase-signaling pathways in vitro.

15 November 2023 in Environmental Toxicology
Verified
Journal Article
Closed access
YSYung‐Luen Shih
Yung‐Luen Shih
SHSheng‐Yao Hsu
Sheng‐Yao Hsu
KLKuang‐Chi Lai
Kuang‐Chi Lai
FCFu‐Shin Chueh
Fu‐Shin Chueh
YHYuan‐Li Huang
Yuan‐Li Huang
HLHsu‐Fen Lu
Hsu‐Fen Lu

8 August 2024 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
HLHsiang-Chun Lai
Hsiang-Chun Lai
JWJui-Chun Weng
Jui-Chun Weng
HHHui-Chi Huang
Hui-Chi Huang
JHJin-Xuan Ho
Jin-Xuan Ho
CKChao-Lin Kuo
Chao-Lin Kuo
SHSheng-Teng Huang
Sheng-Teng Huang

23 August 2024 in Environmental Toxicology
Verified
Journal Article
Closed access
SHSheng‐Yao Hsu
Sheng‐Yao Hsu
E黃E220946282 黃怡萍
E220946282 黃怡萍
THTe‐Chun Hsia
Te‐Chun Hsia
JCJaw‐Chyun Chen
Jaw‐Chyun Chen
SPShu‐Fen Peng
Shu‐Fen Peng
CKChao‐Lin Kuo
Chao‐Lin Kuo